 |
19 Diseases |  |
1 Trial |
|
1 Trial |  |
3312 News |  |
| 12345678910111213...4849» |
- | cefepime hydrochloride / Generic mfg.
Journal: Restoring cefepime activity against multidrug-resistant KPC-producing Klebsiella pneumoniae by combination with boronic acid inhibitors, MB076 and S02030. (Pubmed Central) - Jan 28, 2025
In a survival analysis where mice were infected via the tail vein with KPC-Kpn-1, all mice treated with placebo or cefepime alone (100 mg/kg) died, whereas those treated with a 1:4 molar ratio of cefepime-MB076 survived. Our data demonstrate bactericidal activity and in vivo efficacy of cefepime-MB076 comparable to ceftazidime-avibactam and support the continued development of this combination as a new treatment option for infections caused by class A carbapenemase producing Enterobacterales, particularly KPC-Kpn.
- | Journal: Clinical, Microbiological Profile, and Treatment Outcomes of Carbapenem-Resistant Urinary Tract Infections in a Tertiary Care Hospital. (Pubmed Central) - Jan 28, 2025
Despite effective antibiotic treatment, CR-UTIs are associated with early relapse and recurrence. Newer effective treatment and preventive strategies are required to address this pandemic.
- | Preclinical, Journal: In vitro antimicrobial susceptibility of clinical isolates from adult and paediatric patients in Jordan: Antimicrobial Testing Leadership and Surveillance (ATLAS) 2010-2021. (Pubmed Central) - Jan 16, 2025
More than 92% of Acinetobacter baumannii collected were multidrug-resistant (MDR) and/or carbapenem-resistant (CR), and > 50% susceptibility was reported only to minocycline (62.2% among both MDR and CR isolates)...For Escherichia coli from adults and MDR E. coli, susceptibility to ceftazidime/avibactam, ceftolozane/tazobactam, imipenem, meropenem and meropenem/vaborbactam was 92.1%-98.7%...All S. aureus collected were susceptible to teicoplanin, vancomycin, daptomycin, linezolid and tigecycline, with 96.1% of S. aureus from adults were susceptible to ceftaroline...This study provides valuable information regarding antimicrobial susceptibility in Jordan between 2010 and 2021. Continued monitoring of in vitro antimicrobial susceptibility is critical in the fight against antimicrobial resistance.
- | Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Molecular Characterization and Risk Factors of Carbapenem-Resistant Hypervirulent Klebsiella pneumoniae Isolated from Chinese Tertiary Hospital. (Pubmed Central) - Jan 13, 2025
Resistance was observed against most common antibiotics, with the exception of complete sensitivity to ceftazidime-avibactam...Currently, the hospital predominantly carries K64 CR-hvKp that harbors the bla KPC. Our study found that changing patient beds was an independent risk factor for CR-hvKp infection.
- | Fetroja (cefiderocol) / Shionogi, Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Assessing the Value of New Antimicrobials: Evaluations of Cefiderocol and Ceftazidime-Avibactam to Inform Delinked Payments by the NHS in England. (Pubmed Central) - Jan 13, 2025
Projections of patient numbers could be greatly enhanced by the development of national level linked clinical, prescribing and laboratory data. A practical approach to synthesising these data would be to combine expert assessments of key parameters with a simple generic decision model.
- | Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Disseminated organ and tissue infection secondary to carbapenem-resistant Klebsiella pneumoniae bloodstream infection for acute lymphoblastic leukemia treated with ceftazidime-avibactam: Two case reports. (Pubmed Central) - Jan 12, 2025
A practical approach to synthesising these data would be to combine expert assessments of key parameters with a simple generic decision model. Ceftazidime-avibactam exhibited satisfactory efficacy and safety in the 2 cases of disseminated organ infection secondary to CRKP bloodstream infection following chemotherapy for acute lymphoblastic leukemia.
- | Journal: Advancements in the fight against globally distributed OXA-48 carbapenemase: evaluating the new generation of carbapenemase inhibitors. (Pubmed Central) - Jan 12, 2025
Overall, this comprehensive analysis provides important insights into the effectiveness of new BLIs against OXA-48-producing Enterobacterales, highlighting xeruborbactam, durlobactam, and avibactam as leading candidates. Additionally, BLIs like zidebactam, nacubactam, and taniborbactam also showed potential in addressing the clinical challenges posed by OXA-48-mediated antimicrobial resistance.
- | aztreonam / Generic mfg., Fetroja (cefiderocol) / Shionogi, Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Characterization of carbapenem-resistant Klebsiella pneumoniae from blood cultures in Gaza Strip hospitals, Palestine. (Pubmed Central) - Jan 12, 2025
Additionally, BLIs like zidebactam, nacubactam, and taniborbactam also showed potential in addressing the clinical challenges posed by OXA-48-mediated antimicrobial resistance. The proportion of CRKP among all K. pneumoniae from bloodstream infection in Gaza Strip is high (40?%) and mainly associated with the blaNDM-5-positive high-risk clone ST147.
- | Preclinical, Journal: Detection of carbapenemases in Enterobacterales susceptible in vitro to meropenem. (Pubmed Central) - Jan 12, 2025
The proportion of CRKP among all K. pneumoniae from bloodstream infection in Gaza Strip is high (40?%) and mainly associated with the blaNDM-5-positive high-risk clone ST147. We highlight the importance of tracking carbapenemases for epidemiological control and therapeutic guidance.
- | Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Retrospective data, Journal: Efficacy of ceftazidime-avibactam with or without polymyxin for carbapenem-resistant Klebsiella pneumoniae infections after initial treatment with polymyxin. (Pubmed Central) - Jan 9, 2025
CAZ-AVI salvage therapy demonstrated improved survival outcomes in patients who experienced failure with polymyxin B therapy.IMPORTANCEFor patients with carbapenem-resistant Klebsiella pneumoniae (CRKP) infections, published experience with salvage therapy is limited after the failure of polymyxin-based initial therapy. Here, we found that ceftazidime-avibactam salvage therapy for patients with CRKP infections offers benefit in mortality.
- || Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
PK/PD data, Journal: Ceftazidime-avibactam (CAZ-AVI) pharmacokinetics in critically ill patients undergoing continuous venovenous hemodiafiltration (CVVHDF). (Pubmed Central) - Jan 6, 2025
These results suggest that the CAZ-AVI dose regimens used in this study can be applicable in critically ill patients undergoing CVVHDF, despite the different shape of the PK profiles observed in this population. Further research with a larger patient cohort is warranted to validate and refine these findings.
- | Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Identification of blaKPC-90 in Klebsiella pneumoniae associated with ceftazidime-avibactam resistance and the translocation & truncation of resistant genes mediated by IS26. (Pubmed Central) - Jan 6, 2025
We have also focused on the functional diversity of IS26 in relation to antimicrobial resistance. In the future, it is crucial to pay more attention to the evolution and horizontal transmission of blaKPC.
- | Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Synergistic efficacy of ceftazidime/avibactam and aztreonam against carbapenemase-producing Pseudomonas aeruginosa: insights from the hollow-fiber infection model. (Pubmed Central) - Dec 26, 2024
In the future, it is crucial to pay more attention to the evolution and horizontal transmission of blaKPC. The combination of CZA and aztreonam significantly enhanced the in
- | colistin sulphate / Generic mfg.
Retrospective data, Journal: Efficacy and Safety of Aerosol Inhalation of Colistin Sulfate for the Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infection in the Peri-Operative Period of Liver Transplantation: A Single-Center Retrospective Study. (Pubmed Central) - Dec 26, 2024
The combination of colistin sulfate aerosol inhalation and ceftazidime and avibactam sodium for injection is effective in treating pulmonary CRKP infection during the peri-operative period of liver transplantation. It does not impose an additional burden on liver and kidney function, providing a new treatment option for this type of infection.
- | Fetroja (cefiderocol) / Shionogi, Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Coexistence of seven different carbapenemase producers in a single hospital admission screening confirmed by whole-genome sequencing. (Pubmed Central) - Dec 22, 2024
War-injured patients from Ukraine may carry different clones of multidrug-resistant pathogens with limited treatment options and diverse resistance genes at risk for dissemination. Infection control measures should include early molecular characterization of isolates for detection of routes of transmission.
- | Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Investigation of the synergistic effect of (Pubmed Central) - Dec 21, 2024
The most frequently detected carbapenemase genes were NDM+OXA-48, found in 28 (63.6%) of the isolates.Although the NDM+OXA-48 coexistence predominates in our center, in vitro synergy between CZA and ATM was detected in all of CZA-resistant isolates. Performing the CZA+ATM synergy test and reporting the result is crucial for choosing appropriate treatment in CRKP infection.
- | Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Preclinical, Journal: Bacteriophage treatment is effective against carbapenem-resistant Klebsiella pneumoniae (KPC) in a neutropenic murine model of gastrointestinal translocation and renal infection. (Pubmed Central) - Dec 20, 2024
Bacteriophage decay determined by linear regression of the ln of mean concentrations demonstrated R2 values in plasma of 0.941, kidney 0.976, and cecum 0.918, with half-lives of t1/2 = 2.5 h. Furthermore, a phage-resistant mutant displayed increased sensitivity to serum killing in vitro, but did not show significant defects in renal infection in vivo. A combination of bacteriophages demonstrated significant efficacy alone and synergy with ceftazidime/avibactam in the treatment of experimental disseminated KPC infection in neutropenic mice.
- | Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Preclinical, Journal: The in vitro synergistic and antibiofilm activity of Ceftazidime/avibactam against Achromobacter species recovered from respiratory samples of cystic fibrosis patients. (Pubmed Central) - Dec 20, 2024
The outcomes of this research also suggest that CZA plus colistin, meropenem, or ciprofloxacin were more productive against Achromobacter strains. To our knowledge, this is the first article to evaluate the synergistic and antibiofilm activities of CZA alone or in combination with different agents against Achromobacter species.
- | imipenem/relebactam / Merck (MSD), Vabomere (meropenem/vaborbactam) / Melinta Therap, Menarini, Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Observational data, Preclinical, Journal: In vitro activity and genomic characterization of KPC-producing Klebsiella pneumoniae clinical blood culture isolates resistant to ceftazidime/avibactam, meropenem/vaborbactam, imipenem/relebactam: an Italian nationwide multicentre observational study (2022-23). (Pubmed Central) - Dec 19, 2024
New BLICs were shown to be the most widely active therapeutic option against KPC-Kp clinical isolates collected in Italy. Ceftazidime/avibactam resistance is mainly driven by the expression of KPC variants, whereas the loss of function of the OmpK35 and OmpK36 porins appears to play a key but not exclusive role in the development of meropenem/vaborbactam and/or imipenem/relebactam resistance.
- | Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Detection of KPC-3 producing Escherichia coli ST410 in Volos, Greece. (Pubmed Central) - Dec 19, 2024
Complete genome analysis revealed that E. coli A382 isolate carries a range of virulence factors (iutA, iucC, fimH, fdeC, yehA, yehD, yehC, yehB, cgs, ahha, ccI, hlyE, papC, irp2, fyuA, lpfA, and nlpl) and many other non-beta-lactam resistance determinants, including dfrA14 and sul2, but it is susceptible to aminoglycosides, nitrofurantoin, tigecycline, colistin and ceftazidime-avibactam. In conclusion in this study, we describe the phenotypic and genome characteristics of an extensively drug-resistant E. coli ST410.
- | Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal, Surgery: Testing new waters inmanagement of Stenotrophomonas maltophiliablood stream infection in a post cardiac surgery patient. (Pubmed Central) - Dec 18, 2024
Broth disc elution testing was done to exhibit synergy between CZA and AT. This case highlights the growing need for active interaction between the treating physician and the microbiologist.
- | Journal: Development and validation of a pentaplex PCR assay for rapid detection of blaCTX-M, blaOXA-1, blaCMY, blaNDM and the PBP3 insert in Enterobacterales. (Pubmed Central) - Dec 18, 2024
The pentaplex PCR was effective in detecting four beta-lactamases (blaCTX-M, blaOXA-1, blaCMY, blaNDM) as well as PBP3 inserts. It is expected that using pentaplex PCR as a diagnostic test for resistance detection in clinical practice will improve patient outcomes by providing prompt and targeted treatment.
- | Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Retrospective data, Journal: Considerations regarding a meta-analysis of ceftazidime-avibactam versus other antimicrobial agents for treatment of multidrug-resistant pseudomonas aeruginosa. (Pubmed Central) - Dec 18, 2024
It is expected that using pentaplex PCR as a diagnostic test for resistance detection in clinical practice will improve patient outcomes by providing prompt and targeted treatment. No abstract available
- || Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Preclinical, Retrospective data, Review, Journal, Gram negative: A systematic review and individual bacterial species level meta-analysis of in vitro studies on the efficacy of ceftazidime/avibactam combined with other antimicrobials against carbapenem-resistant Gram-negative bacteria. (Pubmed Central) - Dec 18, 2024
Ceftazidime/avibactam frequently demonstrates synergistic bactericidal activity when combined with various antimicrobials against CR-GNB in in vitro tests. Further pre-clinical and clinical studies are warranted to validate the utility of ceftazidime/avibactam-based combination regimens for CR-GNB infections.
- | Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Retrospective data, Journal: Impact of renal-adjusted ceftazidime/avibactam in patients with KPC-producing Klebsiella pneumoniae bloodstream infection: a retrospective cohort study. (Pubmed Central) - Dec 18, 2024
Dose reduction of ceftazidime/avibactam according to renal function in patients with KPC-Kp BSI seems to be independently associated with higher mortality. This may be possibly due to inadequate exposure provided by the recommended doses for renal impairment.
- || Review, Journal, Gram negative: The Challenge of Treating Infections Caused by Metallo-?-Lactamase-Producing Gram-Negative Bacteria: A Narrative Review. (Pubmed Central) - Dec 17, 2024
In the case of P. aeruginosa with MBL-producing enzymes and with difficult-to-treat resistance, cefiderocol is the preferred option. Further research is needed to optimize treatment strategies and minimize resistance.
- | Journal, Gram negative: [Translated article] National survey and consensus document on dosing strategies for beta-lactam antibiotics against multidrug-resistant gram-negative bacilli (MDR-GNB) in critically ill patients undergoing extracorporeal life-support techniques: The DOSEBL study protocol. (Pubmed Central) - Dec 16, 2024
The availability of extracorporeal life-support techniques has expanded significantly in recent years, alongside a rise in the prevalence of infections caused by MDR-GNB. There is a need to develop evidence-based tools of high quality to standardize dosing and monitoring strategies for new ?-lactam antibiotics.
- | meropenem / Generic mfg., Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Analysis of the Virulence of a Lethal, Carbapenem-resistant Hypervirulent Klebsiella pneumoniae ST-11 Producing KPC-33. (Pubmed Central) - Dec 13, 2024
The ST11-KL64 hv-CRKP clone spread widely in ICU carried numerous resistance and virulence genes, and under antibiotic pressure, they easily underwent mutations resulting in changes in resistance phenotypes, especially in mutations of blaKPC-2 gene in acquiring resistance to CZA. Therefore, clinical attention should be paid to such strains, and the use of antibiotics should be adjusted promptly based on the susceptibility of the strains to antimicrobial agents.
- | Journal: Geographic differences in susceptibility profiles of potential non-class B carbapenemase-producing Enterobacterales isolates against ceftazidime-avibactam, meropenem-vaborbactam, colistin, amikacin, gentamicin, and tigecycline: Data from the Antimicrobial Testing Leadership and Surveillance, 2018-2022. (Pubmed Central) - Dec 13, 2024
Furthermore, the proportions of potential CPE isolates carrying genes encoding blaOXA variants were notably higher among the tested CPE isolates in India, Europe, and Africa/the Middle East regions (99.2%, 53.3%, and 96.7%, respectively) compared to other regions. Trends in resistance to important antibiotics among potential non-class B CPE isolates warrant close monitoring.
- || Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie, voriconazole / Generic mfg.
PK/PD data, Journal: Pharmacodynamic Target Attainment at Infection Site during Treatment of Post-Neurosurgical Ventriculitis Caused by Carbapenem-Resistant Klebsiella pneumoniae with Ceftazidime-Avibactam-Based Regimens: a case report. (Pubmed Central) - Dec 13, 2024
A Klebsiella pneumoniae carbapenemase mutation led to therapy adjustment to ceftazidime/avibactam and polymyxin B, achieving cure. Pharmacokinetic/pharmacodynamic analysis highlights effective ceftazidime/avibactam's brain penetration and bacterial clearance efficacy.
- | ceftazidime / Generic mfg., Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Observational data, Journal: Renal Function and Its Impact on the Concentration of Ceftazidime-Avibactam: A cross-sectional study. (Pubmed Central) - Dec 13, 2024
The findings emphasise the need for individualised dosing strategies of CAZ-AVI based on renal function, for antibiotics used in critically ill patients. The study suggests that underdosing in patients with high CrCl is likely to be common and as such could affect drug effectiveness.
- | Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: NDM-5-producing Klebsiella pneumoniae ST258 in a university hospital in Argentina. (Pubmed Central) - Dec 12, 2024
Our study describes the first outbreak of NDM5-KpST258 at an ICU in Argentina, remarkably associated with considerable changes in the carbapenemase epidemiology. The intrinsic characteristics of ST258 may contribute to increased spread of NDM in hospital settings, resembling KPC-2 dissemination.
- | cefepime/taniborbactam (cefepime/VNRX-5133) / VenatoRx
Journal: Cefepime-taniborbactam activity against antimicrobial-resistant clinical isolates of Enterobacterales and Pseudomonas aeruginosa: GEARS global surveillance programme 2018-22. (Pubmed Central) - Dec 12, 2024
The intrinsic characteristics of ST258 may contribute to increased spread of NDM in hospital settings, resembling KPC-2 dissemination. Cefepime-taniborbactam exhibited potent in vitro activity against Enterobacterales and P. aeruginosa, and inhibited most carbapenem-resistant isolates, including those carrying serine carbapenemases or NDM/VIM MBLs.
- | Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Bloodstream infections caused by carbapenem-resistant Klebsiella pneumoniae: analysis of risk factors, treatment responses and mortality. (Pubmed Central) - Dec 11, 2024
In the CRKP group, the duration of treatment and hospital stay were significantly longer in patients who started treatment three days or later (p?=?0.036/p?=?0.011). This study demonstrates that identifying risk factors for BSIs caused by CRKP and implementing early treatment protocols may lead to a reduction in treatment time and mortality rate.
- | Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Adaptive evolution of extensive drug resistance and persistence in epidemic ST11 KPC-producing Klebsiella pneumoniae during antimicrobial chemotherapy. (Pubmed Central) - Dec 10, 2024
In mouse models, KPC-KP strains with mgrB disruption showed reduced virulence, increased lung colonization and persistence, and a lower inflammatory response, suggesting that mgrB disruption facilitates the transition from acute infection to colonization. This study highlights the complex interplay between antibiotic resistance and bacterial fitness, offering insights into why some patients experience clinical improvement despite severe drug resistance and incomplete bacterial clearance.
- | Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Retrospective data, Journal: Ceftazidime-Avibactam for the Treatment of Carbapenem-Resistant Klebsiella Pneumoniae Infection: A Retrospective, Single Center Study. (Pubmed Central) - Dec 10, 2024
CZA is an effective and important treatment option for CRKP infection even when it is treated as monotherapy. In patients with impaired renal function, a potential impact of CZA dose adjustments on poor survival outcomes has been observed, indicating the need for further research to determine optimal renal dose adjustment strategies.
- | imipenem/relebactam / Merck (MSD), Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Preclinical, Journal: Mutant prevention concentrations, in vitro resistance evolution dynamics, and mechanisms of resistance to imipenem and imipenem/relebactam in carbapenem-susceptible Klebsiella pneumoniae isolates showing ceftazidime/avibactam resistance. (Pubmed Central) - Dec 5, 2024
Genetic and biochemical characterization of the KPC derivatives identified in the resistant mutants confirmed their role in carbapenem resistance. Our data positions imipenem/relebactam as an attractive therapeutic option for combating ceftazidime/avibactam-resistant KPC-producing K. pneumoniae infections.
- | Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Preclinical, Journal: In vivo emergence of resistance to ceftazidime/avibactam through modification of chromosomal AmpC ?-lactamase in Klebsiella aerogenes. (Pubmed Central) - Dec 5, 2024
Whole genome sequencing revealed a differential mutation in AmpC (R148W) in the ceftazidime/avibactam-resistant isolate. Molecular cloning and structural studies confirmed the impact of this substitution, which affects the architecture of the H10 helix, on the evolved resistant phenotype.
- | Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Novel plasmid-mediated CMY variant (CMY-192) conferring ceftazidime-avibactam resistance in multidrug-resistant Escherichia coli. (Pubmed Central) - Dec 5, 2024
Notably, pCMY192 cured in Ec73552 did not confer a growth advantage, while the conjugant exhibited reduced biomass and growth rate, indicating that fitness costs imposed by pCMY192 may have been compensated in Ec73552. Our findings highlight the importance of continuous monitoring of CZA susceptibility to prevent the spread of resistance in clinical settings.
- | KSP-1007 / Sumitomo Pharma, The Kitasato Institute
Preclinical, Journal, Combination therapy, Gram negative: In vitro and in vivo activities of KSP-1007, a broad-spectrum inhibitor of serine- and metallo-?-lactamases, in combination with meropenem against carbapenem-resistant Gram-negative bacteria. (Pubmed Central) - Dec 5, 2024
Our findings highlight the importance of continuous monitoring of CZA susceptibility to prevent the spread of resistance in clinical settings. The MIC90 of MEM/KSP-1007 at 8
- | Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Ceftazidime-avibactam tolerance and persistence among difficult-to-treat KPC-producing Klebsiella pneumoniae clinical isolates from bloodstream infections. (Pubmed Central) - Dec 1, 2024
The MIC90 of MEM/KSP-1007 at 8 Among the K. pneumoniae bloodstream isolates studied, 60%, previously categorized as susceptible to CZA, were, actually, tolerant/persistent to this antibiotic, all these KPC producers.
- | Preclinical, Retrospective data, Journal: In vivo development of resistance to novel ?-lactam/?-lactamase inhibitor combinations in KPC-producing Klebsiella pneumoniae infections: a case series. (Pubmed Central) - Dec 1, 2024
KPC variants are mainly associated with resistance to ceftazidime/avibactam, and some of them (e.g. KPC-14) may also be associated with reduced susceptibility to aztreonam/avibactam and/or cefiderocol. Loss of function of the OmpK35 and OmpK36 porins appears to play a role in the development of resistance to meropenem/vaborbactam and/or imipenem/relebactam, but other mechanisms may also be involved.
- | Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Clinical experience with ceftazidime/avibactam for the treatment of extensively drug-resistant or pandrug-resistant Klebsiella pneumoniae in neonates and children. (Pubmed Central) - Dec 1, 2024
Loss of function of the OmpK35 and OmpK36 porins appears to play a role in the development of resistance to meropenem/vaborbactam and/or imipenem/relebactam, but other mechanisms may also be involved. In our study, ceftazidime-avibactam has been identified as a significant treatment option for resistant Klebsiella pneumoniae infection in critically ill children and premature infants with sepsis and organ failure, and it has been found to be well tolerated.
- | Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Use of epigenetically modified bacteriophage and dual beta-lactams to treat a Mycobacterium abscessus sternal wound infection. (Pubmed Central) - Nov 29, 2024
The rough and smooth strains have similar antibiotic susceptibilities suggesting that the phages specifically eliminated the rough strain. Dual beta-lactam therapy with meropenem and ceftazidime-avibactam provided further clinical improvement, and the phages act synergistically with meropenem in vitro.
- | Fetroja (cefiderocol) / Shionogi
Journal: Cefiderocol in the Successful Treatment of Complicated Hospital-Acquired K. pneumoniae NDM, OXA48 Intraabdominal Infection. (Pubmed Central) - Nov 28, 2024
Because of suspicion of intra-abdominal infection, a broad-spectrum empirical antibiotic therapy was initiated (meropenem, vancomycin, colistin)...Aztreonam, in combination with meropenem/vaborbactam, were included in the treatment and were used together with colistin and tigecycline...On day 27 ceftazidime/avibactam and aztreonam were added, while colistin, meropenem/vaborbactam and fosfomycin were discontinued...A surgical debridement of a source infection, and usage of meropenem/vaborbactam or ceftazidime/avibactam together with aztreonam and colistin allowed survival of the patient but not full recovery. Ultimately, only the cefiderocol monotherapy was effective in treatment of the patient with septic shock of KP NDM OXA 48 etiology.
- | Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Retrospective data, Journal: Clinical characteristics and mortality risk factors of premature infants with carbapenem-resistant Klebsiella pneumoniae bloodstream infection. (Pubmed Central) - Nov 28, 2024
The univariate analysis showed that ceftazidime-avibactam (CAZ/AVI) treatment and appropriate early antimicrobial treatment were significantly associated with survival (P?<?0.05)...It is crucial to administer proper antimicrobial therapy in order to increase survival rates of the patients. CAZ/AVI has the potential to improve outcomes in this particular population; however, further research is required to evaluate the effectiveness of specific treatment in premature infants.
- | Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Observational data, Journal: The Use of Ceftazidime-Avibactam in a Pediatric Intensive Care Unit-An Observational Prospective Study. (Pubmed Central) - Nov 27, 2024
The most frequent use of CAZ-AVI in our PICU was the short-term empirical treatment for patients with previous MDR bacterial colonization and clinical suspicion of bacteremia or sepsis. Furthermore, the combination of CAZ-AVI plus aztreonam could be more effective for CRE infections, especially type Ambler class B as MBL strains.
- | Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Observational data, Retrospective data, Journal: Benefits and Safety of Empiric Antibiotic Treatment Active Against KPC-Producing Klebsiella pneumoniae for Febrile Neutropenic Episodes in Colonized Children with Acute Leukemia-An 8-Year Retrospective Observational Study. (Pubmed Central) - Nov 27, 2024
CAZAVI-based EAT was successful in all FNEs, with a higher success rate without any modification compared to colistin-based EAT, where nephrotoxicity occurred in 14%. Therefore, active EAT, mainly a CAZAVI-based combination, was effective, safe, and associated with low overall and KPC-KpBSI-related mortality.
- | Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal, Gram negative: Gram-Negative Bloodstream Infections in a Medical Intensive Care Unit: Epidemiology, Antibiotic Susceptibilities, and Risk Factors for in-Hospital Death. (Pubmed Central) - Nov 25, 2024
were susceptible to ceftazidime/avibactam...GNBI was a frequent complication among patients in the medical ICU. This study underscored the presence of diverse factors that either heightened or attenuated the risk of in-hospital death.
- | cefepime/zidebactam IV (WCK 5222) / Wockhardt
Preclinical, Journal: In vitro activity of zidebactam/cefepime (WCK 5222), a ?-lactam enhancer/ ?-lactam combination against carbapenem- and colistin-resistant Klebsiella pneumoniae isolates. (Pubmed Central) - Nov 24, 2024
Zidebactam/cefepime combination was highly active against multi-clonal, carbapenem-non-susceptible and colistin-resistant K. pneumoniae isolates producing OXA-48-like (Ambler class D) or/and NDM (Ambler class B) carbapenemases, thus potentially offering a valuable treatment options for infections caused by such pan-drug resistant resistotypes. Though, zidebactam is not an inhibitor of class B and D ?-lactamases, potent activity of zidebactam/cefepime combination is attributable to ?-lactam enhancer mechanism.